Due to a system-wide technology update, we are experiencing extremely high call volume. We appreciate your patience with our operators during this time. Thank you for choosing Fox Chase Cancer Center.
Researchers Find Improved Survival Outcomes in Stomach Cancer Patients Treated at Academic Centers
PHILADELPHIA (February 5, 2021)—Researchers at Fox Chase Cancer Center have found that patients with signet-ring cell gastric carcinoma (SRGC) and non-signet-ring cell gastric carcinoma (NSRGC), two variants of stomach cancer, have better overall survival when they are treated at academic centers compared to community centers.
“I think part of the reason why we see these findings at academic centers is improved standardization of care and volume of experience,” said Maitham Moslim, MD, a Surgical Oncology Fellow at Fox Chase and the lead author of the study.
According to study results, academic centers performed an average of 22 gastric cancer surgeries per year, whereas community centers performed an average of only two.
Gastric adenocarcinoma, or stomach cancer, is the fifth most common cancer and the third leading cause of cancer mortality worldwide. However, most studies of this cancer are based on Eastern populations, where stomach cancer is more prevalent. Due to differences in diet and other environmental factors, findings from these studies cannot necessarily be extended to Western populations, which was an impetus behind conducting this research.
By examining nearly 23,000 patient records from the National Cancer Database, Moslim, Farma, and other Fox Chase researchers compared the overall survival of SRGC and NSRGC patients by cancer stage (1, 2, and 3) and what type of center the patient was treated at.
Their findings showed that patients with stage 1 or 3 NSRGC and stage 2 SRGC had better overall survival when they were treated at academic centers. There was better survival regardless of stage or cancer variant (SRGC versus NSRGC).
“We consider this the first study based on a large-scale database in the Western population,” said Moslim.
The paper, “Treatment at an Academic Cancer Center Confers Better Survival by Stage for Signet-Ring Cell and Non-signet-Ring Cell Gastric Cancer,” was published in Annals of Surgical Oncology.
Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.
For more information, call 888-369-2427